ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "American College of Rheumatology Criteria"

  • Abstract Number: 0106 • ACR Convergence 2024

    IgM and IgG Phosphatidylserine Antibody Detection May Improve Classification Accuracy of SLE and APS

    Christina Donath1, Sara Kahlown1, Ryan Soares2, Kamal Gautam2, Mariam Saleh3, Banki Katalin4 and Andras Perl5, 1SUNY Upstate University Hospital, Department of Medicine, Rheumatology Fellowship Program, Syracuse, NY, 2SUNY Upstate University Hospital, Department of Medicine, Internal Medicine Residency Program, Syracuse, NY, 3SUNY Upstate University Hospital, Syracuse, NY, 4SUNY Upstate University Hospital, Department of Pathology, Syracuse, NY, 5SUNY, Syracuse, NY

    Background/Purpose: Antiphospholipid syndrome (APS) is an autoimmune coagulopathy that causes microvascular and macrovascular thrombosis in both venous and arterial systems. This can occur as a…
  • Abstract Number: 0116 • ACR Convergence 2024

    Assessment of Triple Antiphospholipid Antibody-positive Patients Based on Clinical and Laboratory Domains of 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria

    Reyhan Kose Cobanoglu1, Joann Vega2, Crystal Burgos3 and Doruk Erkan4, 1Aydin Adnan Menderes University School of Medicine, Hospital for Special Surgery, NY, USA, Aydin, Turkey, 2Hospital for Special Surgery, New York, NY, New York, NY, 3Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, New York, NY, 4Hospital for Special Surgery, New York, NY

    Background/Purpose: Triple aPL-positive (lupus anticoagulant test [LA], anticardiolipin antibody (aCL), and anti-β2 glycoprotein-I antibody [aβ2GPI]) patients are at higher risk to develop a  severe clinical…
  • Abstract Number: 0510 • ACR Convergence 2024

    Applying Machine Learning Tools for Personalized Healthcare: Predicting Responses to Biologics in Rheumatoid Patients Through Comorbidity and Blood Test Analysis

    Ahmad Alsaber1, Adeeba Alherz2, Huda Khraiss3, Ghaydaa Aldabie4, balqees alawadhi5, Jiazhu Pan6, Adel Alawadhi7, KHULOUD MOHAMMED8, Hoda Tarakmeh9, Aqeel Muhanna10, Yaser Ali11 and mohammad Khudadah12, and Kuwait Registry for Rheumatic Diseases (KRRD), 1American University of Kuwait, Kuwait, Kuwait, 2Al-Amiri Hospital, Kuwait, Kuwait, 3Monash University, Melbourne, Queensland, Australia, 4ministry of health kuwait, kuwait, Kuwait, 5The Public Authority for Applied Education and Training (PAAET), Kuwait, Al Asimah, Kuwait, 6University of Strathclyde, Glasgow, Scotland, United Kingdom, 7Kuwait University, Kuwait, Kuwait, 8Farwaniya Hospital, Kuwait, Kuwait, 9MOH Kuwait, Kuwait, Kuwait, 10Ministry of Health, Kuwait, Al Farwaniyah, Kuwait, 11Mubarek Al Kabeer Hospital, Kuwait city, Kuwait, 12ministery of health, kuwait, Kuwait

    Background/Purpose: This study aims to employ various machine learning tools to predict the responses of rheumatoid arthritis (RA) patients to biologic treatments, using data from…
  • Abstract Number: 0772 • ACR Convergence 2024

    Global Recruiting Patterns Are Associated with Placebo Response Rates in Clinical Trials of Psoriatic Arthritis

    Andreas Kerschbaumer1, Marlene Steiner2, Suzanne D. Khalili1, Daniel Aletaha3 and Josef Smolen4, 1Medical University of Vienna, Vienna, Wien, Austria, 2Medical University Vienna, Vienna, Wien, Austria, 3Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Wien, Austria, 4Medical University of Vienna, Vienna, Austria

    Background/Purpose: Therapeutic advances of the recent past have led to significant changes in clinical practice when treating patients with psoriatic arthritis (PsA). Since the advent…
  • Abstract Number: 0775 • ACR Convergence 2024

    A Phase 3, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of Inebilizumab in IgG4-Related Disease (MITIGATE): Primary Efficacy and Safety Findings

    John Stone1, Emma Culver2, Arezou Khosroshahi3, Wen Zhang4, Emanuel Della Torre5, Kazuichi Okazaki6, Yoshiya Tanaka7, Matthias Löhr8, Nicolas Schleinitz9, Lingli Dong10, Hisanori Umehara11, Marco Lanzillotta12, Zachary Wallace13, Mikael Ebbo14, George Webster15, Ferran Martinez Valle16, Manu Nayar17, Vinciane Rebours18, Cory Perugino19, Xinxin Dong20, Yanping Wu20, Nishi Rampal20 and Daniel Cimbora20, 1Massachusetts General Hospital , Harvard Medical School, Concord, MA, 2John Radcliffe Hospital, and Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom, 3Emory University, Atlanta, GA, 4Peking Union Medical College Hospital, Dong Cheng Qu, China (People's Republic), 5Ospedale San Raffaele, Milan, Italy, 6University of Occupational and Environmental Health, Osaka, Japan, 7Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, 8Karolinska Institutet, Stockholm, Sweden, 9Aix Marseille university, AP-HM, Marseille, France, 10Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (People's Republic), 11Department of Rheumatology and Immunology, Nagahama City Hospital,, Nagahama, Shiga 526-0043, Japan, Japan, 12IRCCS Ospedale San Raffaele, Milano, Italy, 13Massachusetts General Hospital, Newton, MA, 14Aix-Marseille Université, Marseille, France, 15University College Hospital London, London, United Kingdom, 16Vall d’Hebron Hospital, Barcelona, Spain, 17Freeman Hospital, Newcastle Upon Tyne, United Kingdom, 18Beaujon Hospital, Université Paris-Cité, France, 19Massachusetts General Hospital, Boston, MA, 20Amgen Inc., Thousand Oaks, CA

    Background/Purpose: IgG4-related disease (IgG4-RD) is a rare, systemic, fibroinflammatory disease characterized by unpredictable and recurring flares, leading to organ damage and decreased quality of life.…
  • Abstract Number: 0850 • ACR Convergence 2024

    Assessment of Correlation Between Composite Ultrasonographic Index (ECODAS) and Disease Activity Score 28 in Patients with Rheumatoid Arthritis

    Komal Verma Saluja1, Harshvardhan Khokhar2, Amit Sharma3 and Saurabh Chittora2, 1Government Medical college Kota, Kota, Rajasthan, India, 2Government Medical college Kota, Kota, India, 3Fortis hospital Jaipur, Jaipur, India

    Background/Purpose: Conventional Disease Activity Score 28 has variable sensitivity, subjectivity, inherent bias due to certain variables such as more weightage to joint tenderness and overestimation…
  • Abstract Number: 1230 • ACR Convergence 2024

    Mediating Role of Pain Catastrophizing in Racial Disparities in Knee Osteoarthritis Pain Among Non-Hispanic White and Asian Americans: A Pilot Study

    Chiyoung Lee1, Kent Kwoh2 and Hyochol Ahn1, 1University of Arizona College of Nursing, Tucson, AZ, 2University of Arizona, Tucson, AZ

    Background/Purpose: The prevalence of symptomatic knee osteoarthritis (OA) is projected to increase among racially and ethnically marginalized groups. Although recent studies have begun to delineate…
  • Abstract Number: 1746 • ACR Convergence 2024

    Global Recruiting Patterns Are Associated with Placebo Response Rates in Clinical Trials of Rheumatoid Arthritis

    Andreas Kerschbaumer1, Marlene Steiner2, Pascale Pruckner1, Josef Smolen3 and Daniel Aletaha4, 1Medical University of Vienna, Vienna, Wien, Austria, 2Medical University Vienna, Vienna, Wien, Austria, 3Medical University of Vienna, Vienna, Austria, 4Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Wien, Austria

    Background/Purpose: Therapeutic advances of the recent past have led to significant changes in clinical practice when treating patients with rheumatoid arthritis (RA). Since the advent…
  • Abstract Number: L12 • ACR Convergence 2023

    Efficacy and Safety Outcomes of TAK-279, a Selective Oral Tyrosine Kinase 2 (TYK2) Inhibitor, from a Randomized, Double-blind, Placebo-controlled Phase 2b Trial in Patients with Active Psoriatic Arthritis

    Alan Kivitz1, Elena Tomaselli Muensterman2, Arthur Kavanaugh3, Désirée van der Heijde4, Piotr A. Klimiuk5, Guillermo Valenzuela6, Eva Dokoupilova7, Gabrielle Poirier8, Bhaskar Srivastava8, Sue Dasen8, Xinyan Zhang8, Mona Trivedi2, Haoling Holly Weng9, Ting Hong10, Peter Pothula10 and Xenofon Baraliakos11, 1Altoona Center for Clinical Research, Duncansville, PA, 2Takeda Development Center Americas, Inc., Cambridge, MA, 3Division of Rheumatology, Allergy & Immunology, University of California San Diego Medical School, San Diego, CA, 4Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, 5Department of Rheumatology and Internal Diseases, Medical University of Bialystok and Inter Clinic Piotr Adrian Klimiuk, Białystok, Poland, 6Integral Rheumatology & Immunology Specialists, Plantation, FL, 7Department of Pharmaceutical Technology, Faculty of Pharmacy, Masaryk University and MEDICAL PLUS, s.r.o., Brno and Uherské Hradiště, Czech Republic, 8Nimbus Discovery, Inc., Boston, MA, 9HW MedAdvice LLC, San Diego, CA, 10Takeda Development Center Americas, Inc., Boston, MA, 11Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Bochum, Germany

    Background/Purpose: TYK2 mediates signaling by key cytokines involved in the pathogenesis of immune-mediated inflammatory diseases such as psoriatic arthritis (PsA) and psoriasis (PsO). TAK-279 is…
  • Abstract Number: 1832 • ACR Convergence 2023

    Prevalence of Musculoskeletal Manifestations in Post-acute COVID 19 Patients and Their Quality of Life at Kenyatta National Hospital

    Miriam Kiyiapi, Omondi Oyoo, Peter Oyiro and Frederick Wangai, University of Nairobi, Nairobi, Kenya

    Background/Purpose: Since its discovery in Wuhan, China, severe acute respiratory syndrome coronavirus 2 (SARS CoV 2) has ravaged the globe on an unprecedented scale. While…
  • Abstract Number: 1905 • ACR Convergence 2023

    Implementation of the Clinical Disease Activity Index to Optimize Treat-to-Target Management of Rheumatoid Arthritis at the University of North Carolina Hospitals Rheumatology Specialty Clinic

    Rumey Ishizawar1, Thuyvan Phan2 and Steven Takacs3, 1University of North Carolina at Chapel Hill, School of Medicine, Division of Rheumatology, Allergy, and Immunology, Thurston Arthritis Research Center, Chapel Hill, NC, 2University of North Carolina Hospitals Department of Pharmacy, Apex, NC, 3University of North Carolina Faculty Physicians, Chapel Hill, NC

    Background/Purpose: The 2021 American College of Rheumatology (ACR) guidelines for the treatment of rheumatoid arthritis (RA) recommend a treat-to-target approach to optimize clinical outcomes. This…
  • Abstract Number: 1943 • ACR Convergence 2023

    IgG4-related Disease: 2010-2022 Case Review and Comparative Evaluation of Diagnostic Criteria

    Pablo Martínez Calabuig1, Jorge Juan Fragio1, Roxana Gonzalez Mazarío2, Amalia Rueda Cid3, Mireia Lucía Sanmartín Martínez1, Laura Salvador Maicas1, Laura Abenza Barberá1, María Cristina Sabater Abad1, Antonio Sierra Rivera1, Inmaculada Castelló Miralles1, Juan José Lerma Garrido1, Clara Molina Almela3, Isabel Balaguer Trull1 and Cristina Campos Fernández1, 1Hospital General Universitario Valencia, Valencia, Spain, 2Hospital de Sagunto, Valencia, Spain, 3Hospital General de Valencia, Valencia, Spain

    Background/Purpose: IgG4 immunoglobulin-related disease (IgG4-RD) is a rare, systemic immune-mediated fibro-inflammatory process with an unclear etiology and pathophysiology with the capacity of affecting multiple organs.…
  • Abstract Number: 2323 • ACR Convergence 2023

    An Electronic Health Record-Based Algorithm for Predicting Systemic Lupus Erythematosus Flares: Integrating Clinical Factors and Social Determinants of Health

    Yu Huang1, Lixia Yao2, zhengkang Fan3, Jingchuan Guo1 and Jiang Bian1, 1University of Florida, Gainesville, FL, 2Polygon Health Analytics LLC, Chalfont, PA, 3University of Florida, Gainsville, FL

    Background/Purpose: Systemic lupus erythematosus (SLE) has a relapsing-remitting course, with patients experiencing disease activity flares over time. Flares and prolonged disease activity are associated with…
  • Abstract Number: 2324 • ACR Convergence 2023

    Leveraging ChatGPT for Real-World Systematic Lupus Erythematosus Data Curation from Electronic Health Records: A Feasibility Study

    Lixia Yao, Liwam Gebru, Biruk Aweke, Jay Patel, Ernest Vina, David Fleece and Huanmei Wu, Temple University, Philadelphia, PA

    Background/Purpose: Epidemiologists, health services researchers, and health outcome investigators have begun utilizing real-world data (RWD) to gain valuable insights into disease patterns, treatment outcomes, and…
  • Abstract Number: 0298 • ACR Convergence 2023

    Accuracy of the 2017 European Alliance of Associations for Rheumatology (EULAR)/American College of Rheumatology (ACR) Classification Criteria and Myositis-Specific Autoantibodies-Based Classification Criteria for Classifying Patients with Idiopathic Inflammatory Myopathy

    Tatiana Cobo1, Marta Domínguez2, Anna Pros3, Jose Luís Tandaipán4, Laura Nuño5, JULIA MARTINEZ BARRIO6, Vega Jovani7, Fredeswinda Romero8, Maria Esther Ruiz Lucea9, Eva Tomero Muriel10, Ernesto Trallero Araguás11, Javier Narvaez12, Jordi Camins Fàbregas13, ALBERTO MARIANO RUIZ ROMAN14, Jesus Loarce-Martos15, Annika Nack16, Esmeralda Delgado-Frías17, Francisca Sivera18, carolina Merino19, Antonio Juan Mas20, Alejandro Gómez Gómez1, Jose-Maria Pego-Reigosa21, Maria Martin-Lopez22, Jesús Alejandro Valero23, Carmen carrasco-Cubero24, Mercedes Freire González25, Iñigo Rúa-Figueroa26, Nuria Lozano Rivas27, Julio David Suarez Cuba28, Ana Isabel Turrión Nieves29, María Ángeles Puche Larrubia30 and Patricia Alcocer Amores31, 1Department of Rheumatology, Hospital Universitario Infanta Sofía, Universidad Europea, Madrid, Spain, 2Sociedad Española de Reumatología, Madrid, Spain, 3Department of Rheumatology, Hospital del Mar, Barcelona, Spain, 4Department of Rheumatology, Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain, 5Hospital Universitario La Paz - IdiPAZ, Madrid, Spain, 6Rheumatology, Gregorio Marañon University Hospital, Madrid, Spain, 7Department of Rheumatology, Hospital General Universitario Dr. Balmis, Alicante, Spain, 8IIS-HU Fundación Jiménez Díaz, Madrid, Spain, 9Basurto University Hospital, Bilbao, Spain, 10Rheumatology, Hospital La Princesa, Madrid, Spain, 11Department of Rheumatology, Hospital Universitario Vall d'Hebron, Barcelona, Spain, 12Hospital Universitario de Bellvitge, Barcelona, Spain, 13Department of Rheumatology, Hospital General de Granollers, Barcelona, Spain, 14Department of Rheumatology, Hospital Universitario Virgen del Rocío, Sevilla, Spain, 15Ramón y Cajal University Hospital, Madrid, Spain, 16Department of Rheumatology, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, 17Department of Rheumatology, Hospital Universitario de Canarias, Tenerife, Spain, 18Department of Rheumatology, Hospital General Universitario de Elda, Alicante, Spain, 19Rheumatology Department Hospital Universitario Puerta de Hierro, Majadahonda (Madrid), Spain, 20Hospital Universitario Son Llàtzer, Mallorca, Spain, 21Rheumatology, Hospital do Meixoeiro, Vigo, Spain, 22Hospital 12 de Octubre, Madrid, Spain, 23Department of Rheumatology, Hospital Universitario Donostia, San Sebastián, Spain, 24Department of Rheumatology, Hospital Universitario de Badajoz, Badajoz, Spain, 25Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, 26Rheumatology, Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain, 27Department of Rheumatology, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain, 28Department of Rheumatology, Hospital Universitario Príncipe de Asturias, Madrid, Spain, 29Department of Rheumatology, Hospital Complejo Asistencial Universitario de Salamanca, Salamanca, Spain, 30Department of Rheumatology, Reina Sofia University Hospital, Cordoba, Spain, 31Department of Rheumatology, Hospital Universitario HM Sanchinarro, Madrid, Spain

    Background/Purpose: Limitations of the 2017 EULAR/ACR classification criteria have been suggested for classifying patients with idiopathic inflammatory myopathies (IIMs) and myositis-specific antibodies (MSAs). On this…
  • 1
  • 2
  • 3
  • 4
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology